According to a new report, published by KBV research, The Global Microbial Fermentation Technology Market size is expected to reach $42.4 billion by 2028, rising at a market growth of 5.4% CAGR during the forecast period.
The Antibiotics segment is leading the Global Microbial Fermentation Technology Market by Application in 2021 thereby, achieving a market value of $12.8 billion by 2028. The segment's dominance can be attributable to several factors, including the market release of new antibiotics, the rising emphasis on microbial metabolite R&D, and the high demand for antibiotics globally. The creation of antibiotics depends heavily on microbial fermentation. For instance, according to several studies, 70–80% of all antibiotics that have been identified are made by a single genus of bacteria.
The Bio-Pharmaceutical Companies segment has shown the growth rate of 5.6% during (2022 - 2028). Fermentation using various cell types is the foundation of many biological and biopharmaceutical products. Biopharmaceutical compounds are metabolites with a pharmacological impact that are either intracellular or extracellular. The overall goal of fermentation, consisting of upstream and downstream GMP multi-stage processes, is to produce the necessary biopharmaceutical therapeutic material, which is pure and active, discharged in accordance with the necessary quality standards and specifications.
The Asia Pacific market dominated the Global Microbial Fermentation Technology Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $18.5 billion by 2028. The North America market is exhibiting a CAGR of 5% during (2022 - 2028). Additionally, The Europe market would display a CAGR of 5.2% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/microbial-fermentation-technology-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Biocon Limited, BioVectra Inc. (H.I.G. Capital, LLC), Danone S.A., F. Hoffmann-La Roche Ltd., Koninklijke DSM N.V., Lonza Group AG, Novozymes A/S (Novo Holdings A/S), Corbion N.V., and Bangalore Biotech Labs Pvt. Ltd. (BiOZEEN).
By Application
By End User
By Geography
Companies Profiled
Unique Offerings 
